Clinical Trial

A Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma

Name: A Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma — clinical trial record (NCT07229417)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

To learn if ivonescimab can help to control endocrine-refractory HR+ HER2- and/or TN mILC.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-11-13.

Trial Details

NCT Number	NCT07229417
Lead Sponsor	M.D. Anderson Cancer Center
Conditions	Metastatic Endocrine Refractory, Triple Negative Invasive Lobular Carcinoma
Enrollment	29 participants
Start Date	2025-10-22
Primary Completion	2027-09-30 (estimated)
Study Completion	2029-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-29